The findings indicate that MCM10 serves as a poor prognostic marker in EC, as its overexpression is associated with tumour progression, aggressive clinicopathological features, and reduced overall survival, suggesting that MCM10 may promote EC development and could be a potential therapeutic target (47). Here, MCM10 is linked to neoplasm.